What rules someone out — the short answer

ChondroFiller works by providing an acellular collagen scaffold that the body populates with its own progenitor cells — which means both the patient and the joint environment have to be capable of supporting that repair process. When either is not, the treatment is unlikely to deliver meaningful benefit, and in some situations it carries a safety risk that makes it inadvisable altogether.

Exclusions tend to fall into four broad groups. The first covers safety-based medical contraindications — things such as a known allergy to the scaffold's collagen source, active joint infection, or certain systemic conditions. The second group relates to the joint's biological state: inflammatory diseases and advanced, end-stage joint wear create an environment the scaffold cannot work within. The third concerns mechanics — uncorrected malalignment, ligament instability, or a significant meniscal deficit will undermine any cartilage repair regardless of the product used. The fourth is about defect morphology: very large, deeply excavated, or structurally uncontained defects may exceed what the biomaterial can support.

Some size thresholds also differ between the injectable liquid form and the arthroscopic gel form, so the delivery route matters. A formal clinical assessment, usually including imaging review, is needed to determine which — if any — of these categories applies.

Safety contraindications that rule out treatment entirely

The clearest absolute bar to treatment is a known allergy to collagen or rat-derived (murine) protein. ChondroFiller's scaffold is made from murine-sourced Type I collagen — the same biological origin that confers its tissue-compatible properties also means that anyone sensitised to rat protein cannot receive it safely. This exclusion applies to both the injectable liquid form and the arthroscopic gel form, and it is unaffected by defect size or joint grade.

Active infection — in the joint itself or systemically — is a separate hard exclusion. Introducing a biologic scaffold into an infected environment carries serious risk, and treatment would need to be deferred until infection has fully resolved; for this reason, an infection-related exclusion may be temporary rather than permanent. Active malignancy and tumours near the target joint rule out treatment on comparable safety grounds. Haematopoietic disease and blood or clotting disorders are also listed consistently across clinical sources as contraindications: both the injection process and the subsequent biological repair response depend on normal haematological function.

Pregnancy and breastfeeding complete the safety-based list, excluded on the grounds that no safety data for ChondroFiller have been established in these groups. None of these exclusions reflects a judgement about whether the cartilage defect itself would otherwise be suitable — they arise from the patient's medical status, not the morphology of the joint.

Inflammatory joint disease and why it disrupts scaffold repair

Active synovial inflammation — the kind driven by rheumatoid arthritis, psoriatic arthritis, gout, or pseudogout — creates a joint environment that directly opposes the repair process ChondroFiller depends on.

The scaffold contains no reparative cells of its own. It works by drawing the patient's own progenitor cells in from the surrounding tissue, where they populate the collagen matrix and differentiate into cartilage-forming cells. In a reasonably healthy joint environment, that migration can proceed. In a joint under active immune attack, the inflammatory milieu disrupts cell adhesion, slows or blocks the migration needed for scaffold integration, and may begin to degrade the collagen matrix before repair has a chance to establish.

This is not a limitation unique to ChondroFiller — most cartilage repair strategies perform poorly when applied during active inflammatory disease. The hostile joint environment undermines them in broadly similar ways, which is why active immune-mediated arthropathy features as an exclusion across cartilage repair broadly, not just for this scaffold.

A diagnosis of rheumatoid arthritis or gout does not, however, automatically rule out treatment. Disease activity carries more weight than the diagnostic label. Patients with well-controlled inflammatory arthritis in a stable, low-activity phase may still be considered at assessment; a specialist review of current disease status, imaging, and any ongoing medication would inform that judgement. The decision rests on the joint's present condition, not its history alone.

End-stage or widespread osteoarthritis

Kellgren-Lawrence (KL) grading is a scale radiologists use to rate how much joint space and cartilage remain on an X-ray — Grade I reflects early, minimal change; Grade IV means the cartilage has been lost to the point where bone meets bone with little or no cushioning space between them.

ChondroFiller is suited to joints that still retain meaningful cartilage and space — broadly Kellgren-Lawrence grades I to III. At those levels, the surrounding tissue is still viable enough to supply the progenitor cells the scaffold needs, and there is a stable cartilage border within which repair can establish. Grade IV, by contrast, leaves the joint biologically depleted. With no remaining cartilage to anchor the scaffold's edges and insufficient local cell populations to populate it, the regenerative mechanism that ChondroFiller depends on cannot function as intended.

The same logic extends to generalised or multi-compartmental osteoarthritis, where wear is not confined to a single focal area. When degradation has spread across more than one compartment, the concept of a supported, contained defect — which is central to how this scaffold works — no longer applies.

For hip presentations, Tönnis grade greater than 2 carries equivalent weight as an exclusion on the same reasoning: advanced structural loss removes the biological conditions the treatment requires.

Where end-stage joint disease is the finding, joint replacement becomes the primary pathway — not because ChondroFiller has failed, but because the joint's condition and the treatment's mechanism are no longer a match.

Mechanical problems that must be corrected first

Repairing a cartilage defect while leaving the forces that created it unchanged is a bit like filling a crack in a wall that is still subsiding — the repair may not hold, not because the material is wrong but because the mechanical environment continues to work against it.

Three mechanical factors are assessed as independent preconditions before ChondroFiller is considered.

Coronal malalignment. When the leg axis is significantly off-centre, load shifts away from the joint's natural distribution and concentrates on a narrower area. For the arthroscopic gel form, clinical guidance specifies a threshold of around 5°, beyond which realignment is typically required before cartilage treatment proceeds. For an injectable pathway, the threshold is assessed individually rather than as a fixed figure — the degree of loading abnormality matters more than the angle alone.

Ligament instability. An ACL-deficient knee, or any joint with significant ligament laxity, exposes the cartilage surface to abnormal shear forces with each movement. Placing a scaffold into that environment means the repair tissue must withstand loads it has not been designed to survive. Where ligament reconstruction is indicated, it comes first.

Meniscal deficit. The menisci distribute load across the joint surface and absorb compressive force; a significant ongoing deficit removes that buffering role. Without it, point-loading on the repair site increases in a way the scaffold alone cannot compensate for. Where meniscal tissue can be preserved or addressed, doing so forms part of the preparation for cartilage treatment.

None of these factors permanently disqualifies a patient. Malalignment can often be corrected; ligaments can be reconstructed; meniscal issues can sometimes be managed. Correcting the mechanical environment may open the pathway to ChondroFiller where it would otherwise be unsuitable — a determination made through full mechanical assessment and imaging review.

Defect size and morphology limits

Not all defects of appropriate size are automatically suitable, but size and morphology nonetheless set important outer limits — and the two ChondroFiller delivery forms carry different thresholds.

The arthroscopic gel form carries an explicit exclusion for defects measuring 2.5 cm or more in diameter (roughly 4.9 cm² in area). The injectable liquid form has a broader practical range: published clinical evidence covers defects up to approximately 6 cm², which sits above the gel's ceiling, though this figure reflects clinical practice evidence rather than a powered randomised trial. Defect area is one consideration; the local joint environment — the quality of surrounding cartilage, the subchondral bone condition, and the overall biological capacity of the joint — matters equally in determining whether the injectable form is appropriate for a given presentation.

Two morphological features are consistently associated with poor suitability, regardless of absolute size. Uncontained defects — those lacking a stable border of healthy surrounding cartilage — leave the scaffold without the structural support it needs to remain in position and integrate. Large cystic lesions within the subchondral bone create voids that exceed what the biomaterial can structurally fill; ChondroFiller is a collagen scaffold, not a bone-void filler.

For defects broadly above 2 to 4 cm², autologous cell-based techniques such as ACI or MACI carry a more established evidence base and may represent the more appropriate pathway. Different defect profiles point toward different strategies — an MRI-based assessment is the right starting point for determining which approach suits a given presentation.